Editas Medicine (NASDAQ: EDIT)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Editas Medicine Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Editas Medicine Company Info
Editas Medicine is a pioneer in gene editing technology. The biotech holds exclusive rights to CRISPR, a mechanism for cutting and pasting changes to DNA at precise locations.
News & Analysis
Editas Medicine is a high-risk stock with the potential of a big reward.
These exchange-traded funds track companies in this biotech space.
These CRISPR stocks could be big winners for patient investors.
Which of these rebounding biotech stocks is the better buy right now?
The gene-editing biotech's shares have had a strong two-week run.
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month.
It's been a seesaw month for the clinical-stage gene-editing biotech.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/30/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Podcast Episodes
Earnings Transcripts
EDIT earnings call for the period ending September 30, 2021.
EDIT earnings call for the period ending June 30, 2021.
EDIT earnings call for the period ending March 31, 2021.
EDIT earnings call for the period ending .
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.